Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Cancer
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”),...
Profound Medical to Release First Quarter 2025 Financial Results on May 8 – Conference Call to Follow
TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering...
Victoza Weight Loss: Buy OTC Victoza For Weight Loss Medication Alternative From PhenQ – Real Reviews
phenq Phenq Albany, New York, April 17, 2025 (GLOBE NEWSWIRE) -- In thе last 30 yеars and thе Amеricas havе...
Do Probiotics Make You Poop? Probiotic & Prebiotic Supplement For Constipation From YourBiology
Do Probiotics Make You Poop? Yes and No – Read Probiotics for Constipation: Everything You Need to Know YourBiology YourBiology...
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing...
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused...
Greater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration
In the preliminary findings of a study conducted with the National Taiwan University Hospital, over 50% of sample cases were...
Saudi Arabia and France Strengthen Health Cooperation Through Strategic Agreements in Biotech and Digital Health
PARIS, April 16, 2025 /PRNewswire/ -- On the second day of an official visit to France, His Excellency Fahad Abdulrahman...
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
Vancouver, Canada, April 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology
New patent underscores breadth of application and expansion opportunities for Company’s catheter-based technology Continued progress with growing global patent portfolio...
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting
Update on American Association for Cancer Research Annual Meeting 2025 presentationPRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology...
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
Decoy’s development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer’s extensive scientific knowledge...
OncoC4 Selected to Present at the 2025 AACR Meeting’s Showcase Session
Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody Initial clinical data...
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued...
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds...
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
Exemption from the $5.1 million repayment obligation strengthens LAVA’s balance sheet Underscores focus on cost curtailment and strategic option evaluation...
Oxford Scientists Reveal Sunlight-Powered Anti-Cancer Breakthrough
Scientists reveal GPDT (Green Products Photodynamic Technology) Oxperial BioHealth has revealed a major breakthrough in cancer prevention OXFORD, United Kingdom,...
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2...